Stem Cell Therapy for Hepatitis B, C & Post-Viral Liver Damage

The treatment of viral hepatitis has been transformed in the past decade. For hepatitis C, direct-acting antiviral therapy now achieves sustained virological response in over 95% of patients with short oral regimens. For hepatitis B, modern nucleoside analogues suppress the virus indefinitely with excellent safety. This represents one of the great medical achievements of the modern era.

However, viral cure or suppression does not automatically reverse the liver damage that the virus caused. Patients who lived with chronic hepatitis for years before achieving cure often have established hepatic fibrosis, in some cases progressed to cirrhosis. Even after virus eradication, fibrosis may regress incompletely, and patients with established cirrhosis remain at risk for decompensation, hepatocellular carcinoma, and need for liver transplantation. There is currently no proven medical therapy to reverse established hepatic fibrosis or cirrhosis.

Mesenchymal stem cell therapy is being studied as an emerging adjunctive option for these post-viral patients with established liver damage. The biological rationale is strong — MSCs reduce hepatic inflammation, modulate the fibrotic process, and support hepatic regeneration. The 2026 evidence base, particularly from Asian centres with extensive experience, shows promising signals in selected patients.

A typical 2026 protocol uses allogeneic Wharton's jelly MSCs delivered intravenously at doses of 1-2 million cells per kilogram per infusion. Most patients receive 2-3 infusions over a 5-7 day visit, with consideration of repeat treatment at 6-12 months based on response. Some specialised centres also use direct hepatic artery infusion via interventional radiology, though this is technically more demanding and not universally available.

Pre-treatment evaluation includes detailed liver function assessment (LFTs, INR, albumin, MELD if applicable), fibrosis assessment (FibroScan or recent imaging), upper GI endoscopy if indicated for variceal screening, current viral status, and review of any complications. The treatment plan is coordinated with the patient's hepatologist whenever possible. Antiviral therapy must be continuing if the patient is on suppressive treatment for hepatitis B.

The infusion is straightforward outpatient care. Most patients return home within a week of arrival. Structured 12-month follow-up with serial liver function tests and fibrosis reassessment at 6 and 12 months allows tracking of response. Patients with cirrhosis require ongoing hepatology surveillance for hepatocellular carcinoma regardless of any cellular therapy benefit.